Kornimate/medical-research-clean huggingface dataset:
role and value of inflammatory markers in brain tumors : a case controlled study

Conditions: Brain Tumor

Summary: this study is a case controlled analytical study that analyzes the relationship between levels of inflammatory markers with the type of brain tumor. samples of 35 people were then categorized according to the variables above and analyzing to measure its significance

this study is a case controlled analytical study to find the relationship between levels of inflammatory markers in patients with brain tumors. samples were collected from patients at haji adam malik hospital in medan, then the patient's blood serum was taken to be checked for these variables. sample collection began in march - september 2020. the sample obtained was 35 people who met the inclusion and exclusion criteria. inclusion criteria: 1. willing to be a sample 2. complete medical records 3. head scan and head contrast mri have been performed to confirm the patient's diagnosis with a brain tumor exclusion criteria: 1. the patient's age is over 70 years 2. patients with high comorbidities such as kidney failure, heart disease, diabetes, and others 3. patients with a history of brain tumor surgery or previous brain tumor treatment samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. once categorized, the levels of inflammatory markers was examined. specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. the results of these examinations are grouped on a nominal scale, and analyzed statistically. based on this analysis, it will be determined whether there is a significant relationship between levels of inflammatory markers in the incidence of brain tumors.

Eligibility criteria:
inclusion criteria: 1. willing to be a sample 2. complete medical records 3. head scan and head contrast mri have been performed to confirm the patient's diagnosis with a brain tumor exclusion criteria: 1. the patient's age is over 70 years 2. patients with high comorbidities such as kidney failure, heart disease, diabetes, and others 3. patients with a history of brain tumor surgery or previous brain tumor treatment

Keywords: brain tumor, inflammation, procalcitonin, crp, nlr
evaluation of the body slimming effect of tci904

Conditions: Body Weight; Metabolic Syndrome

Summary: to assess the efficacy of lactobacillus delbrueckii ssp. bulgaricus tci904 on body slimming


Eligibility criteria:
inclusion criteria: * age ≥ 20 * bmi ≥ 23 or male body fat ≥ 25%, female body fat ≥ 30%. * history of atherosclerotic cardiovascular disease (including cerebrovascular disease, coronary heart disease, peripheral vascular disease) or type 2 diabetes or have any of the following factors: age men ≥ 45 years, women ≥ 55 years or amenorrhea, hypertension, hyperlipidemia (total cholesterol \> 200 mg/dl or low-density lipoprotein cholesterol ldl-c \> 130 mg/dl or triglyceride tg \> 130 mg/dl), high-density lipoprotein cholesterol hdl-c \< 40 mg/dl. * if people have routinely taken drugs for lowering blood sugar, blood pressure or blood lipids, there is no significant dose change within three months (variation ≤ 20%). * volunteers who are willing to participate in and complete the trial plan after explaining by the researchers, and sign the consent form. exclusion criteria: * history of diabetic ketoacidosis. * medical records documented cerebrovascular disease, acute myocardial infarction or coronary artery bypass surgery or placement of coronary artery stents or peripheral vascular disease within the last 6 months. * known acute infectious illness within the past month with \> 7 days of antibiotics. * known short-term use of steroids, nsaids, anti-rejection drugs, interferon, immunomodulators or changes in long-term doses due to any factors in the past month. * have used any weight loss drugs (including orlistate, lorcaserin, liraglutide) within the past three months. * history of any cancer in the past 5 years or still receiving cancer treatment. * patients with abnormal liver function (got or gpt greater than 3 times the upper limit of normal) or known cirrhosis. * patients with abnormal kidney function (egfr \< 30 ml/min/1.73 m\^2). * patients with a history of alcoholism. * have participated in any other interventional clinical research within the last month. * pregnant and lactating women. * known history of allergy to the test substance. * patients who are judged inappropriate by the trial host.
use of omegaven for treatment with parenteral nutrition associated liver disease

Conditions: Parenteral Nutrition-related Hepatitis

Summary: to provide parenteral fat emulsion prepared from fish oil (omega-3 fatty acid emulsion, omegaven®) to patients with liver disease (pnald).

this is a compassionate use protocol for patients with pnald who have failed traditional treatment to receive omegaven through an ind. omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.

Eligibility criteria:
inclusion criteria: 1. the patient will be pn dependent and unable to meet nutritional needs solely by enteral nutrition. 2. patient will be \<18 years of age. 3. direct bilirubin \> 2.0mg/dl 4. the patient must have failed standard therapies to prevent progression his/her liver disease. exclusion criteria: 1. other causes of chronic liver disease (hepatitis c, cystic fibrosis, biliary atresia, and alpha 1 anti-trypsin deficiency). 2. patients who are allergic to eggs/shellfish 3. patients who have severe hemorrhagic disorders.
italian translation of the michigan hand outcomes questionnaire

Conditions: Hand Fracture; Hand Osteoarthritis; Hand Injury Wrist; Hand Sprain; Wrist Injuries; Wrist Fracture; Wrist Arthritis

Summary: patient-reported outcome measures (proms) are important clinical items for evaluating injuries and recovery of the hand. some of the most used questionnaires, unfortunately, are not available in italian.

patient-reported outcome measures (proms) are important clinical items for evaluating injuries and recovery of the hand. some of the most used questionnaires, unfortunately, are not available in italian. this poses a problem when evaluating italian speaking patients. our aim is to develop a culturally adapted italian version of the michigan hand questionnaire. there is no risk involved for the patients, as the task of the recruited patients is to answer a survey (online and in clinics).

Eligibility criteria:
inclusion criteria: * age \> 18 years * native italian speakers * wrist/hand pathology * trauma (fractures, tendon injuries, etc.) * chronic pathology, the pathology has been present for at least 1 month (tenosynovitis, chronic arthrosis pain, rheumatic hand or wrist disorders) * in case of hand/wrist surgery: at least 4 weeks have elapsed since surgery to avoid that the patient could not perform certain actions evaluated by the scale, for example lifting a pan or shopping bags, due to normal post-operative precautions. * full possession of mental capacity exclusion criteria: * age \< 18 years * non-native italian speakers of italian, thus also excluding second generation swiss italians ("secundo") * mental incapacity * upper limb in cast/locked by splint (criterion in chung's article 98) at the time of the evaluation
investigation of acrysof® iq panoptix™ presbyopia-correcting intraocular lens (iol) model tfnt00

Conditions: Cataract

Summary: the purpose of this study is to investigate visual outcomes and assess safety at 12 months (330-420 days) post bilateral implantation of the acrysof® iq panoptix™ presbyopia-correcting iol.

this study will be conducted in regions where the test article is approved at the time of study start.

Eligibility criteria:
inclusion criteria: * diagnosis of bilateral cataracts with planned cataract removal by phacoemulsification with a clear cornea incision; * able to comprehend and willing to sign informed consent and complete all required postoperative follow-up procedures; * clear intraocular media other than cataract in both eyes; * other protocol-specified inclusion criteria may apply. exclusion criteria: * clinically significant corneal abnormalities including corneal dystrophy, inflammation or edema; * ocular trauma, corneal transplant, retinal conditions, degenerative eye disorders, or color vision deficiencies; * glaucoma (uncontrolled or controlled with medication) or ocular hypertension; * pregnant or lactating; * expected to require ocular surgical or retinal laser treatment; * other protocol-specified exclusion criteria may apply.
does preventive dexketoprofen reduce pain after orthognathic surgery

Conditions: Pain, Postoperative

Summary: background the purpose of this study was to evaluate the effect of a single-dose intravenous dexketoprofen administration for preventive analgesia on postoperative pain and reducing swelling in double jaw surgery. material and methods the authors designed a prospective, randomized, and double-blind cohort study. patients who have class iii malocclusion were randomly divided in two groups. 50 mg intravenous dexketoprofen trometamol were administrated 30 minutes before incision in treatment group, while intravenous sterile saline was administrated 30 minutes before incision in placebo group. the primary predictor variable was treatment group. primary outcomes were pain, swelling and 24-hour opioid intake. patient- controlled analgesia with tramadol was given for management of postoperative pain. other variables were demographic and operation related parameters. visual analogue scale was used to evaluate postoperative pain. 3dmd face system (3dmd, usa) was used to measure postoperative swelling. data were analysed using two independent samples t test and mann whitney u test.


Eligibility criteria:
inclusion criteria: * inclusion criteria for this study were as follows; * patients, * 18-45-year-olds, * asa i status, * class iii malocclusion, * elective double jaw surgery. exclusion criteria: * exclusion criteria were asa ii and above, * drug allergy, * liver and kidney failure, * pregnant or breastfeeding, * long-term use of pain relievers such as nsaids and opioids, * diabetes

Keywords: preventive analgesia pain swelling orthognathic surgery dexketoprofen 3dmd
extended therapy of drotrecogin alfa (activated) 4 vs 7 days infusion

Conditions: Sepsis; Hypotension

Summary: the purpose of this study is to determine whether continued administration of drotrecogin alfa (activated) up to additional 72 hours - after the so far recommended 96 hour infusion period - results in a more rapid resolution of hypotension in severe septic patients.


Eligibility criteria:
inclusion criteria: * severe sepsis patients treated with 96 hour infusion of commercial drotrecogin alfa (activated) * continue requirement of vasopressor support after 96 hour commercial infusion exclusion criteria: * patients require extensive surgical procedures within next 3 days * patients with platelet count below 30,000/mm3 * patients receiving therapeutic heparin of 15,000 units/day and more * patients not expected to survive 24 days * patients contraindicated as to the country specific registration
incidence of delirium after cardiac surgery surgery

Conditions: Delirium

Summary: delirium is a common problem that occurs after cardiac surgery. the incidence of delirium after cardiac surgery is estimated to be 26-52%, with a significant percentage being hypoactive delirium1-4.postoperative delirium has been associated with higher hospital costs, longer lengths of hospital stay, increased likelihood of institutionalization, increased risk for dementia, and increased morbidity and mortality.5-7 . the overall purpose of this study was to determine the incidence and perioperative factors that predispose to cause delirium in postoperative cardiac surgery patients in our icu


Eligibility criteria:
inclusion criteria: * patients 18 years old and older of both sexes * patients who signed an informed consent * patients scheduled for cardiac surgery with extracorporeal circulation (coronary-artery bypass grafting (cabg), cardiac valve replacement (cvr), combined cabg + cvr, excision of cardiac myxoma) exclusion criteria: * patients who refused to participate before or after operation; * patients in poor general condition; * patients with preoperative dementia, delirium or illiterate, psychiatric or mental disorder (epilepsy, schizophrenia, depression); * patients who died intraoperatively or within the first 6 hours after the procedure.

Keywords: delirium;post-cardiac surgery;adults
safety of three formulations of ketasyn administered for 14 days in healthy elderly

Conditions: Alzheimer's Disease

Summary: ac-1202 (ketasyn) is a nutritional beverage currently being studied in neurodegenerative conditions including alzheimer's disease. the current study is a randomized, open-label trial to compare the safety, tolerability, and pk profiles of 3 formulations of ketasyn administered on a daily basis for 14 days, with and without a 7-day titration period, in normal, healthy elderly volunteers.

sixty healthy, elderly volunteers between the ages of 55 and 85 will be enrolled at one of four clinical sites in the tampa/st. petersburg area. subjects with a history of gi inflammatory conditions (e.g., ibs or diverticulitis) or other clinically significant abnormalities will be excluded from enrollment. subjects will be randomized to one of two dosing regimens (with or without a 7-day titration period) and to one of three formulations of ketasyn containing the identical amount of active ingredient, but different amounts of proteins and carbohydrates. subjects assigned to group 1 will receive 10 grams active ingredient daily on days 1-7, followed by a daily dose of 20 grams active ingredient on days 8-14. subjects assigned to group 2 will receive 20 grams active ingredient on days 1-14. all subjects will have clinic visits on day 1 and 14; subjects assigned to group 1 will also have a clinic visit on day 8. subjects will fast prior to each clinic visit and have vital signs and routine lab tests performed prior to dosing. a standard breakfast will be served along with the study product, following which blood samples will be collected for product concentration levels.

Eligibility criteria:
inclusion criteria: * no clinically significant abnormal findings on physical exam, vital signs, medical history, ecg, or laboratory results exclusion criteria: * type 1 or uncontrolled type 2 diabetes * history of or current inflammation of gi system, e.g. ibs, diverticular disease, gastric or duodenal ulcers, severe gerd requiring daily medication * history (within past 60 days) of infections * clinically significant renal, hepatic, or hematologic abnormalities
losartan and inflammation in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the purpose of the study is to examine if a specific drug called losartan (cozaar ®), generally used to treat high blood pressure and to protect kidneys from damage in patients suffering from diabetes mellitus, will have any effect on the nasal inflammation in patients with cystic fibrosis (cf). the study will be performed at the pulmonary division at the university of miami, cincinnati children's medical hospital center, university of kansas medical center and university of alabama-birmingham.


Eligibility criteria:
inclusion criteria: * cf patients homozygous for f508del and on current treatment with orkambi™ for at least 3 months * age \>12 years * forced expiratory volume at one second (fev1) \>/= 40% of predicted exclusion criteria: * female patients not willing to adhere to strict birth control (combination of two methods) * pregnancy * history of intolerance to angiotensin receptor blockers (arbs) * treatment with angiotensin converting enzyme (ace) inhibitor * npd response to zero chloride (0cl)/isoproterenol of \> - 6.6 mv at screening (evidence of detectable cftr activity at baseline) * regular use of nsaids or potassium supplementation, treatment with aliskiren, on anticoagulation * oral corticosteroid use within 6 weeks * exacerbation requiring treatment within 6 weeks * active treatment for mycobacterial infections * significant hypoxemia (oxygen saturation \ 45 mmhg), clinical evidence of cor pulmonale * untreated arterial hypertension (systolic blood pressure \>140 mm hg, diastolic blood pressure \> 90 mmhg) * blood pressure less than 90 mm hg systolic while standing * cardiac, renal (creatinine 1.5 times normal limit), hepatic (lfts \> 3x normal upper limit), neurological, psychiatric, endocrine or neoplastic diseases that are judged to interfere with participation in study * known renal artery stenosis * concomitant airway disorders other than cf, such as allergic bronchopulmonary aspergillosis (abpa). * subjects with prior thoracic surgery
the safety study of autologous tils therapy for patients with glioblastoma multiforme.

Conditions: Glioblastoma Multiforme, Adult

Summary: the study is to evaluate the safety and efficacy of tumor infiltrating lymphocyte (til) therapy for patients with maligant glioblastoma multiforme. autologous tils should be given by intravenous infusion after 5 days of lymphodepletion treatment.


Eligibility criteria:
inclusion criteria: 1. age: 18 to 80 years old; 2. has at least one measurable tumor foci; 3. ecog score range : 0-2; 4. expected survival time: ≥ 3 months; 5. all screening labs should be performed 7 days prior to registration.the laboratory results need to meet below criteria: * absolute white blood cell counts (wbc) ≥ 3.0×10\^9/l； * platelet count (plt) ≥ 100×10\^9/l； * hematological absolute neutrophil count (anc) ≥ 1.5×10\^9/l； * hemoglobin (hgb) ≥ 90g/l; * albumin (absolute) ≥ 2.8g/dl; * serum alt/ast ≤ 2.5×uln (for patients with liver metastasis ≤ 5×uln); * total bilirubin (tbil) ≤ 1.5×uln (for patients with liver metastasis ≤ 2×uln); * renal serum creatinine or measured or calculated a creatinine clearance (cr) ≤1.5×uln or≥ 50 ml/min for participant; * ast/alt (sgot) ≤ 2.5×uln (for patients with liver metastasis ≤ 5×uln); * international normalized ratio (inr) ≤ 1.5; * prothrombin time (pt) and activated partial thromboplastin time (aptt) ≤ 1.5×uln; 6. female participant of childbearing potential should have a negative result of human chorionic gonadotropin (hcg) test. the participants must take contraception during the entire clinical follow-up. 7. be willing and able to provide written informed consent/assent for the trial. exclusion criteria: 1. has systemic active infection and requiring treatment; 2. has severe physical or mental illness; 3. has active rheumatic disease; 4. has any kinds of organ transplantation; 5. being pregnant or lactating; 6. enrolled in other clinical trials within 4 weeks prior to registration; 7. has a known history of human immunodeficiency virus (hiv) (hiv 1/2 antibodies), active hepatitis b (e.g., hbsag reactive) or hepatitis c; 8. other conditions that the researcher considered to be excluded; 9. has taken blow treatment before enrollment: * received systemic immunosuppressive treatments, aside from corticosteroids within 14 days of treatment; * plan to get inactivated vaccine 28 days prior/during, or 60 days post the treatment.

Keywords: glioma tils glioblastoma multiforme
melanoma biomarker study

Conditions: Metastatic Melanoma

Summary: the purpose of this study is to measure the level of a specific protein, cxcl1, in the blood of patients with untreated, metastatic (stage iv) melanoma. these levels will be compared to blood levels in normal controls. if the levels are elevated in metastatic melanoma, further studies to determine if this correlates with presence and extent of disease will be pursued.

malignant melanoma has rapidly increased in incidence over the past thirty years, at a rate of roughly 3% per year. in 2005, approximately 59,000 new cases of melanoma were diagnosed with 8000 deaths. while the majority of early melanomas can be surgically cured, advanced melanoma has an extremely poor prognosis. current chemotherapy and immunotherapy options for advanced melanoma still offer response rates of only 10-20%. thus, the elucidation of biomarkers in melanoma, both diagnostic and prognostic, is an important area for investigation. cxcl1 is a chemokine whose expression is upregulated in melanoma. we postulate that cxcl1 plays an important role in the progression of melanoma to invasive disease. our hypothesis states that serum cxcl1 levels correlate with the presence of melanoma. aims: 1. to measure serum levels of cxcl1 in untreated, metastatic melanoma patients and to compare to serum cxcl1 levels in normal controls. 2. to measure and compare centrally and peripherally collected serum cxcl1 levels in untreated, metastatic melanoma. blood will be collected from metastatic melanoma patients on one occasion, both peripherally and centrally. control will have blood collected peripherally on one occasion. the blood will be processed and then tested in a blinded, batched fashion.

Eligibility criteria:
inclusion criteria: 1. histologic diagnosis of melanoma; primary may be cutaneous, mucosal or ocular. 2. evidence of metastatic disease based on standard ajcc staging. 3. willing to give written informed consent. 4. willing and able to comply with protocol procedures. 5. at least 18 years of age. 6. no prior chemotherapy, immunotherapy, or radiotherapy. 7. are able to safely donate 50 ml of blood. 8. have a central venous catheter in place (this will not be placed for participation in this trial) exclusion criteria: 1. known diagnosis of a chronic inflammatory disease, ie: rheumatoid arthritis, systemic sclerosis, inflammatory bowel disease 2. known diagnosis of nyha class 3 or 4 congestive heart failure 3. are unable to safely donate 50 ml blood 4. known hiv, hepatitis b, or hepatitis c infection. 5. any malignancy within 5 years, other than melanoma (for patients); have any malignancy within the past 5 years including melanoma (for normal controls). basal cell and squamous cell skin cancers are permitted in all participants.

Keywords: metastatic melanoma untreated biomarker
exactech vantage total ankle system post market clinical follow-up - us only

Conditions: Ankle Rheumatoid Arthritis; Arthritis of Ankle; Failure, Prosthesis

Summary: the objectives of this study are to evaluate the performance and safety of the vantage total ankle system. this study will follow subjects for a period of up to 10 years post-surgery.


Eligibility criteria:
inclusion criteria: * patient is indicated for total ankle arthroplasty * patient is skeletally mature * patient is mentally capable of completing follow-up forms * patient will be available for follow-up out to 10 years * patient has been deemed a candidate for ankle replacement by diagnosis of the investigator * patient is willing and able to read and sign a study informed consent form exclusion criteria: * patient with excessive bone loss at the ankle joint site * patient with severe osteoporosis * patient with complete talar avascular necrosis * patient with active osteomyelitis * patient with infection at the ankle site or infection at distant sites that could migrate to the ankle * patient with sepsis * patient with vascular deficiency in the involved limb * patient with neuromuscular inadequacy (e.g. prior paralysis, fusion and or inadequate abductor strength) * patient with neuropathic joints * patient with neurological or musculoskeletal disease or loss of function that may adversely affect movement of the lower limb, gait, or weight bearing * patient with poor soft tissue coverage around the ankle * patient with charcot arthropathy * previous ankle arthrodesis with excision of the malleoli * excessive loads as caused by activity or patient weight - per investigator discretion * skeletally immature patients (patient is less than 21 years if age at time of surgery) * patient with dementia * patient with known metal allergies * patient who is pregnant